ObjectiveTo investigate the clinical efficacy and safety of triptorelin acetate for girls with idiopathic central precocious puberty (ICPP). Methods166 cases of ICPP girl who were admitted to our hospital from January 2003 to October 2017 were selected as subjects. According to the wishes of the girls or their families, they were divided into the treatment group (88 cases) and the control group (78 cases). The girls in the treatment group were treated with triptorelin acetate, and the girls in the control group were not treated with drugs. The menarche age, height development, uterine volume and left and right ovarian size were compared between the two groups. ResultsThe menarche age in the treatment group was significantly higher than that in the control group (P＜0.05). There were no significant differences in pre-treatment height and hereditary height between the two groups (P＞0.05). The height of the treatment group was significantly higher than their hereditary height at 24 months after menarche and was significantly higher than that of the control group. The height of the control group was significantly lower than their hereditary height at 24 months after menarche. The difference was statistically significant (P＜0.05). There were no significant differences in blood testosterone levels between the two groups before treatment and 24 months after menarche (P＞0.05). There were no significant differences in uterine volume and left and right ovary size between the two groups before treatment,(P＞0.05). The uterine volume and left and right ovaries of the two groups were significantly greater than before treatment at 24 months after menarche (P＜0.05), but there were no significant differences in uterine volume and left and right ovarian size between the two groups (P＞0.05). ConclusionTriptoril acetate treatment of ICPP girls can delay menarche and promote height development. In the short term, no polycystic ovary syndrome and high testosteroneemia occur.

无